Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.52
−$0.01 · -0.40%
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Latest quote
$2.52
−$0.01 · -0.40%
Regular session · ET · Market data may be delayed.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
47
Fair Value
Sentiment
55
Mixed
Risk
74
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 17K USD | 23K USD | 8K USD | 23K USD |
| Gross profit | — | −17K USD | −23K USD | −8K USD | −23K USD |
| Research and development | 21.19M USD | 14.12M USD | 17.33M USD | 15.08M USD | 9.21M USD |
| Selling, general, and administrative | 15.96M USD | 13.5M USD | 14.04M USD | 12.61M USD | 11.31M USD |
| Operating expenses | 37.14M USD | 27.62M USD | 31.38M USD | 27.69M USD | 20.52M USD |
| Interest income | 2.38M USD | 4.05M USD | 4.34M USD | 877K USD | 6K USD |
| Depreciation and amortization | 16K USD | 17K USD | 23K USD | 8K USD | 23K USD |
| Operating income | −37.14M USD | −27.62M USD | −31.38M USD | −27.69M USD | −20.52M USD |
| Net income | −34.77M USD | −25.5M USD | −30.09M USD | −26.96M USD | −20.61M USD |
Company facts updated Sep 5, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 2, 2026 | 1:15 | — | — |
Stock split | Apr 20, 2018 | 1:12 | — | — |
Stock split | Aug 26, 2016 | 1:15 | — | — |
Effective Feb 2, 2026
1:15
Effective Apr 20, 2018
1:12
Effective Aug 26, 2016
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
